1. Bioactive sphingolipids act as angiogenic modulators in the ovary: novel strategies to tackle pathological blood vessels.

SCOTTI, LEOPOLDINA; PASCUALI, NATALIA; ABRAMOVICH, DALHIA; DE ZÚÑIGA, IGNACIO; OUBIÑA, GONZALO; PARBORELL, FERNANDA

Workshop; International Postgraduate Workshop on Metabolic diseases and vascular dysfunction mechanisms.; 2018

N Pascuali, L Scotti, G Oubiña, I de Zúñiga, D Abramovich, F Parborell. The development of new blood vessels in the ovary is essential to guarantee the necessary supply of nutrients and hormones to promote follicular growth and corpus luteum formation 1,2. When the delicate angiogenic balance is disrupted, it can cause serious alterations in ovarian function. Sphingolipids are involved in the regulation of death, proliferation, migration and angiogenesis, among other cellular functions 3-6. The major bioactive sphingolipid metabolites include sphingosine, ceramide, sphingosine-1-phosphate (S1P) and ceramide-1-phosphate (C1P). We and several authors have demonstrated that S1P and C1P are key mediators in the processes of apoptosis and angiogenesis in different tissues, in both physiological and pathological conditions 7-11. In this work, we have aimed to explore the role of sphingolipids in blood vessel anomalies occurring in three different ovarian pathologies: ovarian hyperstimulation syndrome (OHSS), premature ovarian insufficiency (POI) and advanced reproductive age (ARE). We propose that S1P and C1P are potential candidates for novel therapeutic strategies to tackle angiogenic anomalies in pathological conditions.